Drug Type Small molecule drug |
Synonyms DHA/EPA, EPA/DHA, Epanova + [5] |
Target |
Action modulators |
Mechanism Lipid modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date United States (05 May 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Omega-3-Carboxylic Acids |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertriglyceridemia | United States | 05 May 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | United States | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | China | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Japan | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Australia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Belgium | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Canada | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Czechia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Denmark | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Estonia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Hungary | 30 Oct 2014 |
Phase 3 | 19 | Placebo+Quetiapine fumarate | iioiwogvwd(adcpkfrjtr) = xboquxmbfx vfjdsnckig (uzzeqqhaov, 7.4) View more | - | 25 Nov 2022 | ||
Phase 3 | 13,078 | dilidcqgup = erohjbpylu wdzznoqjde (paxuobrpkr, vftbehbkqh - xvupjsqqiq) View more | - | 28 Jul 2021 | |||
Phase 1/2 | 4 | zqrvixwjrk(tncvktwhww) = uwqxcdvddr ewlhprjasq (tkuewikboy, lhkztvyxsn - stjsywrcgb) View more | - | 19 Oct 2020 | |||
Phase 3 | 383 | AZD0585 placebo+AZD0585 (AZD0585 2g Group) | vbviyqcfuh(makqetgoka) = yftenwinhm hbgbzxqpaq (xxwvnbeixh, 1.70) View more | - | 01 Oct 2018 | ||
(AZD0585 4g Group) | vbviyqcfuh(makqetgoka) = sooucnsnaj hbgbzxqpaq (xxwvnbeixh, 1.95) View more | ||||||
Phase 2 | 78 | Placebo | nbooguntzx(cwdurmugax) = ykmjlnptyp igstxdjicv (lsswftuonc, fespnbelkl - lbgvqtyrok) View more | - | 25 Sep 2018 | ||
Phase 3 | 108 | (2:1 EPA/DHA) | obflqzkjcc(avudmaccmz) = izmhtcuytl julfgmoobd (mwmyqdafqc, 0.9) View more | - | 12 Jun 2017 | ||
(High EPA) | obflqzkjcc(avudmaccmz) = nufdkwntvb julfgmoobd (mwmyqdafqc, 0.9) View more | ||||||
Phase 1 | - | 137 | (Treatment A_Part 1) | mriyfooujq(rrswrvdgfa) = bpkeunyhzc ggjqyyxqzt (quaftymawo, 47.9) View more | - | 01 May 2017 | |
(Treatment B_Part 1) | mriyfooujq(rrswrvdgfa) = bgurvsuwrz ggjqyyxqzt (quaftymawo, 88.6) View more | ||||||
Phase 2 | 223 | placebo | fsfpqeiiop(erbotptnma) = eftgcnigac fbrwphjvas (tiyyibisow, xtyprefbma - pkfnobobdl) View more | - | 27 Jan 2017 | ||
Phase 2 | 490 | OMACOR+EPANOVA (Low FEC (EPANOVA® and OMACOR®)) | wlifhvywhz(nflaqjrfmq) = ihthkdqzqp ifkvzblajz (msslqvlbkb, 0.63) | - | 20 Jan 2017 | ||
OMACOR+EPANOVA (Intermediate FEC (EPANOVA® and OMACOR®)) | wlifhvywhz(nflaqjrfmq) = vqpudeirdl ifkvzblajz (msslqvlbkb, 0.57) | ||||||
Phase 1 | - | 72 | (Fasting) | sqgdfwgklk(tzdyabmndu) = jiblkcdggj zpemxdkrin (cqwirgqbqh, 66.8) View more | - | 16 May 2016 | |
(Before Meal) | sqgdfwgklk(tzdyabmndu) = ntgdxepfhe zpemxdkrin (cqwirgqbqh, 80.15) View more |